Sunflower Pharmaceutical: Report for the third quarter of 2024

SZSIOct 29 00:00 · Announcements

Sunflower Pharmaceutical Group (002737.SZ): The net income for the first three quarters was 0.587 billion yuan, a year-on-year decrease of 31.06%.

Gelonghui October 28th | Sunflower Pharmaceutical Group (002737.SZ) announced its third quarter report for 2024, achieving revenue of 2.967 billion yuan in the first three quarters, a year-on-year decrease of 29.95%; net income attributable to shareholders of the listed company was 0.587 billion yuan, a year-on-year decrease of 31.06%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.46 billion yuan, a year-on-year decrease of 2.05%; basic earnings per share was 1.0 yuan.

Gelonghui FinanceOct 28 23:20

Sunflower Pharmaceutical Group (002737.SZ) released its performance for the first three quarters, with a net income of 0.587 billion yuan, a year-on-year decrease of 31.06%.

sunflower pharmaceutical group (002737.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...

Zhitong FinanceOct 28 20:35

Express News | Sunflower Pharmaceutical Group plans to invest 10 million yuan to establish a wholly-owned subsidiary.

BreakingsOct 24 15:43

Sunflower Pharmaceutical Group (002737.SZ): Ursodeoxycholic acid capsules have been accepted for market approval.

Gelonghui October 14th | Sunflower Pharmaceutical Group (002737.SZ) announced that its holding subsidiary, Sunflower Pharmaceutical Group (Tangshan) Biopharmaceutical Co., Ltd., recently received the "Acceptance Notice" for the application for registration and listing of ursodeoxycholic acid capsules issued by the National Medical Products Administration. The intended indications (or main functions) of the above-mentioned pharmaceuticals are: (1) Gallbladder cholesterol stones must be stones that can be penetrated by X-rays, while gallbladder contraction function must be normal; (2) Cholestatic liver disease (such as: primary biliary cirrhosis); (3) Bile reflux gastritis.

Gelonghui FinanceOct 14 15:49

Sunflower Pharmaceutical: Semi-Annual Report 2024

SZSIAug 28 00:00 · Announcements